Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) announced the FDA granted a formal evidentiary public hearing under 21 CFR Part 12 to review CDER's proposed refusal of the company's sNDA for HETLIOZ® in jet lag disorder.

The FDA letter is dated March 2, 2026; the hearing follows a D.C. Circuit ruling that set aside the agency's earlier refusal in August 2025 and remanded the matter for resolution or hearing.

Positive

• FDA granted formal evidentiary hearing under 21 CFR Part 12
• D.C. Circuit set aside FDA refusal in August 2025 and remanded the sNDA
• Regulatory transparency milestone: first such drug approval hearing in over 40 years

Negative

• Approval remains unresolved—hearing follows FDA's proposed refusal
• Commercial approval for jet lag is still pending despite court remand

Key Figures

Shelf registration size: $200,000,000 Shelf reference price: $7.43 per share Persistence duration: 7 years +5 more

8 metrics

Shelf registration size $200,000,000 S-3 shelf filed Feb 12, 2026

Shelf reference price $7.43 per share Last reported sale on Feb 11, 2026 in S-3 filing

Persistence duration 7 years Time Vanda cites advocating on HETLIOZ® jet lag application

Historical gap over 40 years Time since last similar FDA Part 12 drug approval hearing

Case number 24-1049 Vanda Pharmaceuticals Inc. v. FDA in D.C. Circuit

Regulation cited 21 CFR Part 12 Governs the formal evidentiary hearing process

Section cited 21 CFR § 12.120 Defines issuance of the presiding officer’s initial decision

Publication date March 3, 2026 Press release announcement date

Market Reality Check

Price: $8.17 Vol: Volume 2,598,027 is below...

low vol

$8.17 Last Close

Volume Volume 2,598,027 is below the 20-day average of 4,524,719, suggesting no outsized trading response. low

Technical Shares at $8.17 are above the 200-day MA of $5.47, but sit 14.9% below the 52-week high and well above the 52-week low.

Peers on Argus

VNDA fell 8.31% while key biotech peers like NMRA, TNXP, OMER, CADL, and LXEO al...

VNDA fell 8.31% while key biotech peers like NMRA, TNXP, OMER, CADL, and LXEO all showed positive moves (0.99–12.28%), indicating a stock-specific reaction to this FDA hearing news.

Common Catalyst Peer headlines highlighted conference participation and a Nasdaq uplisting, unrelated to VNDA’s FDA hearing, reinforcing a company-specific catalyst.

Previous Fda approval Reports

5 past events · Latest: Feb 20 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 20	FDA drug approval	Positive	+41.5%	Full FDA approval of BYSANTI™ for bipolar I disorder and schizophrenia.
Dec 30	FDA drug approval	Positive	+25.5%	FDA approval of NEREUS™ for motion‑induced vomiting with strong efficacy data.
May 05	NDA acceptance	Positive	+0.4%	FDA acceptance of Bysanti™ NDA with decision date set for early 2026.
Apr 23	FDA hearing delay	Negative	-1.8%	Company challenged FDA bureaucrats over delays in tradipitant hearing scheduling.
Mar 31	NDA submission	Positive	-2.1%	Initial submission of Bysanti™ NDA for bipolar I disorder and schizophrenia.

Pattern Detected

FDA-related milestones have often driven strong positive reactions on outright approvals (NEREUS, BYSANTI), while procedural or hearing-related disputes have produced modest or negative moves.

Recent Company History

Over the past year, Vanda has advanced multiple FDA interactions. Approvals for NEREUS™ and BYSANTI™ each generated sizable gains, while earlier Bysanti NDA filing and acceptance drew mild price responses. In contrast, a 2025 press release criticizing FDA delays around a tradipitant hearing slightly weighed on shares. Today’s landmark hearing for HETLIOZ® in jet lag fits the pattern of process-heavy news, distinct from clear approvals that historically produced larger upside.

Historical Comparison

+12.7% avg move · Past FDA-approval-tagged releases for VNDA averaged a 12.69% move, mostly higher on clear approvals....

fda approval

+12.7%

Average Historical Move fda approval

Past FDA-approval-tagged releases for VNDA averaged a 12.69% move, mostly higher on clear approvals. Today’s -8.31% reaction to a procedural HETLIOZ® hearing contrasts with that pattern.

FDA interactions have progressed from Bysanti™ NDA submission and acceptance to full approvals for NEREUS™ and BYSANTI™, while Vanda simultaneously pursues hearings to challenge prior negative decisions.

Regulatory & Risk Context

Active S-3 Shelf · $200,000,000

Shelf Active

Active S-3 Shelf Registration 2026-02-12

$200,000,000 registered capacity

An effective S-3 shelf filed on Feb 12, 2026 allows Vanda to offer up to $200,000,000 in various securities for general corporate purposes. The registration is not yet effective and shows 0 recorded usage, but it provides capacity for future equity or debt issuance.

Market Pulse Summary

This announcement details a rare FDA evidentiary hearing under 21 CFR Part 12 for HETLIOZ® in jet la...

Analysis

This announcement details a rare FDA evidentiary hearing under 21 CFR Part 12 for HETLIOZ® in jet lag disorder, following a court ruling that criticized the agency’s prior review. Historically, Vanda’s clearest value inflections came with outright approvals like NEREUS™ and BYSANTI™, while process-heavy disputes drew mixed reactions. Investors may focus on hearing outcomes, HETLIOZ® label expansion prospects, use of the $200,000,000 shelf, and how these interact with the company’s broader CNS portfolio.

Key Terms

supplemental new drug application, sNDA, center for drug evaluation and research

3 terms

supplemental new drug application regulatory

"proposal to refuse approval of Vanda's supplemental new drug application (sNDA) for HETLIOZ"

A supplemental new drug application is a request submitted to regulatory authorities to make changes to an existing approved medication, such as adding new uses, strengths, or formulations. For investors, it signals that a pharmaceutical company is seeking approval for new product developments or expanded applications, which can impact the company's future sales, market potential, and stock value.

sNDA regulatory

"proposal to refuse approval of Vanda's supplemental new drug application (sNDA) for HETLIOZ"

A SNDA (Subordination, Non‑Disturbance and Attornment Agreement) is a legal pact among a property owner’s lender, the owner’s tenants, and sometimes the landlord that sets who keeps lease rights if the property is sold or a mortgage is enforced. Think of it as a rulebook that decides whether a tenant can stay and keep paying rent or must answer to a new owner after a foreclosure. For investors, an SNDA matters because it protects predictable rental income, clarifies who has priority on claims against a property, and therefore affects a property’s value and the security of related loans.

center for drug evaluation and research regulatory

"review the Center for Drug Evaluation and Research's (CDER) proposal to refuse approval"

A U.S. federal regulatory office that reviews and decides whether new and existing prescription and over‑the‑counter drugs are safe and effective for patients. Its decisions set the rules for whether a medicine can be sold, what claims can be made about it, and what warnings are required. Investors watch it like a gatekeeper: approval unlocks market access and revenue, while delays or rejections create risk and uncertainty for a drug maker.

AI-generated analysis. Not financial advice.

WASHINGTON, March 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a formal evidentiary public hearing to review the Center for Drug Evaluation and Research's (CDER) proposal to refuse approval of Vanda's supplemental new drug application (sNDA) for HETLIOZ^® (tasimelteon) in the treatment of jet lag disorder.

The FDA confirmed the decision to grant a hearing in a letter from the Office of the Commissioner dated March 2, 2026. The hearing will proceed under 21 CFR Part 12, after which the presiding officer will issue an initial decision pursuant to 21 CFR § 12.120.

Granting a formal evidentiary public hearing in response to a proposed refusal to approve a drug application is a rare and highly significant regulatory step. Publicly available records and historical accounts indicate that the FDA has not granted such a hearing under 21 CFR Part 12 in the context of drug approvals for decades—potentially over 40 years—underscoring the gravity of the legal and scientific issues raised by Vanda.

"We are encouraged by the FDA's decision to grant a formal evidentiary hearing on the proposed refusal of our jet lag application for HETLIOZ^®," said Mihael H. Polymeropoulos, M.D., President, Chief Executive Officer, and Chairman of the Board of Vanda Pharmaceuticals. "This procedural victory reflects Vanda's 7-year persistence in advocating for fairness and the rigorous pursuit of scientific truth on behalf of patients. At the same time, it represents a significant reform step by the FDA toward greater transparency—the first such formal drug approval hearing in over 40 years."

This development follows Vanda's prior success in Vanda Pharmaceuticals Inc. v. FDA, case no. 24-1049, before the U.S. Court of Appeals for the D.C. Circuit. In August 2025, the court set aside the FDA's earlier refusal to approve HETLIOZ^® for jet lag disorder. The ruling held that the FDA unlawfully failed to adequately engage with Vanda's evidence—despite statistically significant results from clinical trials—and criticized the agency's cursory treatment of expert, evidence-based submissions. The court remanded the matter, directing the FDA to finally resolve Vanda's sNDA or commence a hearing.

HETLIOZ^® is currently approved in the United States for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome. The pending sNDA seeks to expand approval to treat jet lag disorder, a condition that affects millions of travelers worldwide — including business travelers, athletes, and rapidly deployed troops — for which there is currently no FDA-approved therapeutic.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About HETLIOZ^®

HETLIOZ^® (tasimelteon) is a melatonin‑receptor agonist, approved in the United States for the treatment of Non‑24‑Hour Sleep‑Wake Disorder and nighttime sleep disturbances associated with Smith‑Magenis Syndrome. For full U.S. Prescribing Information for HETLIOZ^®, including indications and Important Safety Information, visit www.hetlioz.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including, but not limited to statements regarding the upcoming formal evidentiary hearing, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the outcome of the formal evidentiary hearing. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-announces-fda-grants-landmark-hearing-for-hetlioz-in-jet-lag-disorder-the-first-drug-approval-hearing-in-over-40-years-302702448.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What did Vanda (VNDA) announce on March 3, 2026 about HETLIOZ® and the FDA?

Vanda announced the FDA granted a formal evidentiary public hearing to review a proposed refusal. According to the company, the FDA letter is dated March 2, 2026 and the hearing will proceed under 21 CFR Part 12 after a D.C. Circuit remand.

Why is the FDA hearing for VNDA's HETLIOZ® considered significant by investors?

The hearing is significant because such Part 12 drug approval hearings are rare and signal serious legal and scientific issues. According to the company, this is the first formal drug approval hearing in over 40 years, reflecting elevated regulatory scrutiny and visibility.

What was the outcome of the court case Vanda Pharmaceuticals Inc. v. FDA (case no. 24-1049)?

The D.C. Circuit set aside the FDA's earlier refusal and remanded the sNDA in August 2025. According to the company, the court found FDA failed to adequately engage with Vanda's evidence and directed resolution or a hearing.

Does the FDA decision on March 2, 2026 mean HETLIOZ® is approved for jet lag disorder?

No; the FDA granted a hearing to review the proposed refusal but did not approve the sNDA. According to the company, the hearing will precede a presiding officer's initial decision under 21 CFR § 12.120.

What current US indications does HETLIOZ® hold and what is VNDA seeking with the sNDA?

HETLIOZ® is approved for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome nighttime sleep disturbances. According to the company, the pending sNDA seeks expansion to treat jet lag disorder, for which no FDA-approved therapy currently exists.